Virax Biolabs Group Stock (NASDAQ:VRAX)

Virax Biolabs Group Limited is a biotechnology firm that specializes in the sale, distribution, and promotion of diagnostic testing kits, medical technology, and personal protective equipment (PPE). Its offerings are designed to aid in the prophylaxis, identification, diagnosis, and management of risks associated with viral illnesses within the immunology sector. Under its ViraxClear brand, the company provides a range of diagnostic tools, including rapid antibody IgG/IgM assays, antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody assessments. Additionally, it supplies medical technology and PPE products, such as employee safety gear marketed under the ViraxCare brand, alongside infrared thermometers, pulse oximeters, face coverings, gloves, and other protective items. Virax Biolabs also distributes nebulizer devices and intelligent wearable technology engineered to remind staff about social distancing protocols. The company operates an e-commerce platform where its ViraxClear and ViraxCare product lines are available for purchase. Its diverse clientele encompasses medical facilities, pharmacies, research laboratories, healthcare systems, corporate entities, individual purchasers, and both public and private organizations. With operations spanning Europe, South America, the Asia Pacific region, Sub-Saharan Africa, and other international markets, the company maintains a global presence. Established in 2021 and headquartered in London, United Kingdom, the entity was formerly known as Virax Biolabs (Cayman) Limited, officially adopting its current name in September 2021.